Non-HDL-C can provide a better risk estimation compared with LDL-C, in particular in HTG combined with diabetes, metabolic syndrome, or CKD. Elevated levels of non-HDL Cholesterol are treatable by intensifying lipid-lowering agents, as well as ongoing lifestyle modification. All of the currently available lipid-lowering agents (statins, fibrates, niacin, fish-oil products, and intestinally active agents) decrease non-HDL-C levels.
According to the ESC/EAS Guidelines for the management of dyslipidaemia, the specific target for non-HDL-C should be 0.8 mmol/L (30 mg/dL) higher than the corresponding LDL-C target; this corresponds to the LDL-C level augmented by the cholesterol fraction which is contained in 1.7 mmol/L (150 mg/dL) of TG, which is the upper limit of what is recommended.
https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Dyslipidaemias-Management-of
There are several algorithms available to assess CVD risk and when to initiate treatment.
https://statindecisionaid.mayoclinic.org/index.php/statin/index?PHPSESSID=7t5s8vcrtmlilekvejb4pd91g4
https://academic.oup.com/eurheartj/article/41/1/111/5556353
https://www.escardio.org/Journals/ESC-Journal-Family/European-Journal-of-Preventive-Cardiology
